Does diagnosis of metabolic syndrome predict the likelihood of peripheral arterial disease as defined by a low ankle-brachial index?

Abstract

Background

There is limited information about whether a diagnosis of metabolic syndrome (MS) predicts peripheral arterial disease independently of diabetes. This study assessed whether MS adds prognostic information beyond that relating to diabetes in the identification of a low ankle–brachial index (ABI).

Design

Cross-sectional population-based study of people aged 50–75 years.

Methods

Eight hundred and fifty-eight participants were randomly selected. The likelihood of low ABI (< 0.90) was calculated according to MS status before and after excluding diabetes. The National Cholesterol Education Panel and the International Diabetes Federation (IDF) definitions of MS were used.

Results

The prevalence of National Cholesterol Education Panel-defined and IDF-defined MS, and low ABI was 57.8, 61.1 and 7.5%, respectively. When there were participants with three or more criteria for MS, participants with only three criteria, and participants with four or five criteria were compared with participants without MS, the odds ratio for low ABI was 1.89 (95% confidence interval, 1.08–3.30), 1.34 (0.70–2.60) and 2.70 (1.45–5.03), respectively. The association of MS and low ABI lost statistical significance after excluding diabetes. No difference was observed using the IDF definition of MS. Conclusion Screening of participants with MS does not improve the identification of abnormal ABI provided by diabetes. Eur J Cardiovasc Prev Rehabil 15:693–697 © 2008 The European Society of Cardiology

Keywords

ankle-brachial index cardiovascular risk factors metabolic syndrome peripheral arterial disease

Get full access to this article

View all access options for this article.

References

Selvin

Erlinger

. Prevalence of risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004; 110:738–743.

Moler

. Peripheral artery disease. Identification and implications. Arch Intern Med 2003; 163:2306–2314.

Wautrecht

Dramaix

De Backer

Kornitzer

. Ankle brachial index is an independent predictor of all-cause and coronary mortality in healthy middle-aged working Belgian men after eighteen year follow-up Eur J Cardiovasc Prev Rehabil 2006; 13 (Suppl 1):S26–S27.

Garni

Witt

Howard

Erwin

Garni

Somers

Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol 2007; 49:403–414.

Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105–1187.

Wang

Ruotsalainen

Moilanen

Lepistö

Laakso

Kuusisto

. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007; 28:857–864.

Stern

Williams

Hunt

. Impact on diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 2005; 6:3–6.

Sone

Mizuno

Fujii

Yoshimura

Yamasaki

Ishibashi

Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005; 28:1463–1471.

Kahn

Buse

Ferrannini

Stern

. The metabolic syndrome: time for a critical appraisal. A Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289–2304.

10.

Fadini

Coracina

Inchiostro

Tiengo

Avogaro

de Kreutzenberg

. A stepwise approach to assess the impact of clustering cardiometabolic risk factors on carotid intima-media thickness: the metabolic syndrome no-more-than additive. Eur J Cardiovasc Prev Rehabil 2008; 15:190–196.

11.

The Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe (DECODE) Study Group. Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. Eur J Cardiovasc Prev Rehabil 2007; 14:192–199.

12.

Medrano

Boix

Cerrato

Ramirez

. Incidence and prevalence of ischaemic heart disease and cerebrovascular disease in Spain: a systematic review of the literature. Rev Esp Salud Pública 2006; 80:5–15.

13.

Isomaa

Almgren

Tuomi

Forsen

Lahti

Nissén

Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683–689.

14.

Friedewald

Levy

Fredrickson

. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.

15.

Matthews

Hosker

Rudenski

Naylor

Treacher

Turner

. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–419.

16.

O'Braien

De Gaudemairs

Bobrie

Agabiti Rosei

Vaisse

. Proceedings from the First International Consensus Conference on Self-Blood Pressure Measurement. Devices and validation. Blood Press Monit 2000; 5:93–100.

17.

Resnick

Lindsay

McGrae

Devereux

Jones

Fabsitz

Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109:733–739.

18.

Wattanakit

Folsom

Duprez

Weatherley

Hirsh

. Clinical significance of a high ankle-brachial index: insights from the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2007; 190:459–464.

19.

Grundy

Brewer

Cleeman

Smith

Lenfant

; for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition Circulation 2004; 109:433–438.

20.

Alberti

KGM

Zimmet

Shaw

; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition Lancet 2005; 366:1059–1062.

21.

Ford

. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 2005; 28:1769–1777.

22.

Tong

Kong

Yang

Ronald

The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III Definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007; 30:1206–1211.

23.

Cull

Jensen

Retmakaran

Holman

. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus. United Kingdom Prospective Diabetes Study 78. Circulation 2007; 116:2119–2126.

24.

Olijhoek

van der Graaf

Banga

Algra

Rabelink

Visseren

. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004; 25:342–348.

25.

Wang

Ruotsalainen

Moilanen

Lepistö

Laakso

Kuusisto

. Metabolic syndrome and incident end-stage peripheral vascular disease. A 14-year follow-up study in elderly Finns. Diabetes Care 2007; 30:3099–3104.

26.

Rana

Jansen

Zwinderman

Nieuwdorp

van Aalst-Cohen

Jukema

Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. Diabetes Care 2006; 29:1125–1127.

27.

Lahoz

Vicente

Laguna

García-lglesias

Taboada

Mostaza

. Peripheral artery disease in subjects over 60 years of age. Diabetes Care 2006; 29:148–150.